Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meds Apotek AB (publ)FRA:24R +0.46%9 EV-to-EBIT is 76.55 as of Sep. 08, 2026. GuruFocus rates FRA:24R with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 885 Retail - Cyclical companies, Meds Apotek AB (publ) ranks worse than 93.45% on this metric.
Meds Apotek AB (publ) (FRA:24R) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Meds Apotek AB (publ)'s Enterprise Value for the quarter that ended in Jun. 2026 was €28.77 Mil.
Meds Apotek AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Internet Retail subindustry, Meds Apotek AB (publ)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meds Apotek AB (publ) EV-to-EBIT vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Meds Apotek AB (publ)'s EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Meds Apotek AB (publ)'s EV-to-EBIT falls into.
Meds Apotek AB (publ)'s current Enterprise Value is €37.13 Mil.
Meds Apotek AB (publ)'s EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meds Apotek AB (publ) (FRA:24R) has a EV-to-EBIT of 76.55 as of Sep. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Meds Apotek AB (publ) and its competitors. According to the industry distribution chart, Meds Apotek AB (publ) ranks #827 out of 885 companies in the Retail - Cyclical industry, placing it in the top 93.4%.
Is Meds Apotek AB (publ)'s EV-to-EBIT too high?
Meds Apotek AB (publ)'s current EV-to-EBIT is 76.55. The Retail - Cyclical industry median EV-to-EBIT is 13.02. Meds Apotek AB (publ)'s value of 76.55 is 487.9% above this industry median. Based on the distribution chart, Meds Apotek AB (publ) ranks #827 out of 885 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Meds Apotek AB (publ) has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Meds Apotek AB (publ)'s EV-to-EBIT compare to AMZN and BABA?
According to the Retail - Cyclical industry distribution chart, Meds Apotek AB (publ) ranks #827 out of 885 companies for EV-to-EBIT. This places Meds Apotek AB (publ) in the lower half of its industry. The industry median EV-to-EBIT is 13.02. Meds Apotek AB (publ)'s value of 76.55 is 487.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Retail - Cyclical company?
The median EV-to-EBIT among Retail - Cyclical companies is 13.02, based on 885 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Meds Apotek AB (publ)'s current EV-to-EBIT of 76.55 is 487.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Meds Apotek AB (publ) and its competitors. For the Retail - Cyclical industry, the median EV-to-EBIT is 13.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Meds Apotek AB (publ)'s current EV-to-EBIT is 76.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meds Apotek AB (publ) stock overvalued right now?
Meds Apotek AB (publ) (FRA:24R) has a current EV-to-EBIT of 76.55. The current EV-to-EBIT is 76.55 and 487.9% above the Retail - Cyclical industry median of 13.02. Meds Apotek AB (publ)'s overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Meds Apotek AB (publ) (FRA:24R), the current EV-to-EBIT is 76.55 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Meds Apotek AB (publ) is a full-scale online pharmacy that sells prescription and over-the-counter medicines with permission from the Medical Products Agency, the Swedish Food Agency and the E-Health Agency. The company's pharmacy products include everything in health, well-being, dietary supplements, beauty products, children's products, fitness products, food and drink and home & household products.
9GF Score
Get the complete analysis for FRA:24R
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:24R has been successfully added to your 
